The promise of antibody–drug conjugates (ADCs) is the specific targeting of highly potent cytotoxic agents to malignant disease without adversely affecting normal tissues. We may be on the verge of fulfilling that promise. This moment has been more than 25 years in the making and has required technology development in every facet of the conception and execution of ADCs. In this issue of the Journal, Verma et al.1 describe the positive results of their phase 3 trial comparing the ADC trastuzumab emtansine to the combination of lapatinib and capecitabine in women with advanced breast cancers that are strongly positive for . . .
No takes yet. Share an insight, caveat, or question.
Teicher et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: